Victory Capital Management Inc Bio Atla, Inc. Transaction History

Victory Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$19.0 - $30.95 $201,913 - $328,905	-10,627 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$29.44 - $43.74 $2,325 - $3,455	-79 Reduced 0.74%	10,627 $313,000
Q2 2021 Aug 03, 2021	SELL	$38.07 - $56.17 $19,948 - $29,433	-524 Reduced 4.67%	10,706 $454,000
Q1 2021 May 04, 2021	BUY	$32.41 - $70.91 $39,864 - $87,219	1,230 Added 12.3%	11,230 $571,000
Q4 2020 Feb 01, 2021	BUY	$31.02 - $35.16 $310,200 - $351,599	10,000 New	10,000 $340,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.